Literature DB >> 15447678

Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.

Masanori Yamada1, Takeshi Iwatsubo, Yoshikuni Mizuno, Hideki Mochizuki.   

Abstract

To elucidate the role of alpha-synuclein in the pathogenesis of Parkinson's disease, both human alpha-synuclein transgenic mice and targeted overexpression of human alpha-synuclein in rat substantia nigra using viral vector-based methods have been studied, however, little is known about the pathogenetic changes of dopaminergic neuron loss. Therefore, it is necessary to address whether the pathogenetic changes in brains with Parkinson's disease are recapitulated in these models. Here, we used the recombinant adeno-associated viral (rAAV) vector system for human alpha-synuclein gene transfer to rat substantia nigra and observed approximately 50% loss of dopaminergic neurons at 13 weeks after infection, which was comparably slower than the progression of neurodegeneration reported in other studies. In the slower progression of neurodegeneration, we identified several important features in common with the pathogenesis of Parkinson's disease, such as phosphorylation of alpha-synuclein at Ser129 and activation of caspase-9. Both findings were also evident in cortical tissues overexpressing alpha-synuclein via rAAV. Our results indicate that overexpression of alpha-synuclein via rAAV apparently recapitulates several important features of brains with Parkinson's disease and dementia with Lewy bodies, and thus alpha-synucleinopathy described here is likely to be an ideal model for the study of the pathogenesis of Parkinson's disease and dementia with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15447678     DOI: 10.1111/j.1471-4159.2004.02728.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  91 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

2.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

Review 3.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

4.  Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.

Authors:  Katerina E Paleologou; Abid Oueslati; Gideon Shakked; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Claudio O Fernandez; Adrian Schmid; Fariba Chegini; Wei Ping Gai; Diego Chiappe; Marc Moniatte; Bernard L Schneider; Patrick Aebischer; David Eliezer; Markus Zweckstetter; Eliezer Masliah; Hilal A Lashuel
Journal:  J Neurosci       Date:  2010-03-03       Impact factor: 6.167

5.  Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.

Authors:  Lei-Lei Chen; Ju-Xian Song; Jia-Hong Lu; Zhen-Wei Yuan; Liang-Feng Liu; Siva Sundara Kumar Durairajan; Min Li
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-13       Impact factor: 4.147

6.  Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

7.  Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates.

Authors:  Hemraj B Dodiya; Tomas Bjorklund; James Stansell; Ronald J Mandel; Deniz Kirik; Jeffrey H Kordower
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

8.  Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states.

Authors:  Ronald L Klein; Robert D Dayton; Jason B Tatom; Cynthia G Diaczynsky; Michael F Salvatore
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy.

Authors:  Margot Fournier; Jérémie Vitte; Jérôme Garrigue; Dominique Langui; Jean-Philippe Dullin; Françoise Saurini; Naïma Hanoun; Fernando Perez-Diaz; Fabien Cornilleau; Chantal Joubert; Héctor Ardila-Osorio; Sabine Traver; René Duchateau; Cécile Goujet-Zalc; Katerina Paleologou; Hilal A Lashuel; Christian Haass; Charles Duyckaerts; Charles Cohen-Salmon; Philipp J Kahle; Michel Hamon; Alexis Brice; Olga Corti
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

10.  Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies.

Authors:  Tiago Fleming Outeiro; Aleksey Kazantsev
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.